RCS - Germfree - Germfree Announces Appointment of 4 Board Members

adidas AGAnnouncement

28/02/2024 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240228:nRSb6864Ea&default-theme=true

RNS Number : 6864E  Germfree  28 February 2024

Germfree Announces Appointment of 4 Board Members

ORMOND BEACH, FL / ACCESSWIRE / February 28, 2024 / Germfree announces the
appointments of Dorothy Puhy, Karen Flynn, Kerry Ingalls and Helga Salling as
independent non-executive members of its Board of Directors.

"We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of
Directors. Their counsel will guide strategic alternatives, aid Germfree in
capitalizing on opportunities, and navigate future challenges. Leveraging
their collective expertise, the Board will play a pivotal role in driving
sustainable growth and ensuring long-term success. Germfree's story is one of
relentless innovation, unwavering commitment to quality, and profound impact
on global health. We remain committed to advancing innovation and maintaining
our position as a leader in critical environment equipment, cleanrooms, and
laboratories. Our Board will help Germfree to capitalize on emerging trends
and technological advancements, particularly in the rapidly evolving fields of
cell and gene therapy," said Kevin Kyle, CEO at Germfree.

Dorothy Puhy brings considerable experience to the Germfree Board and is
well-recognized for her financial expertise. She dedicated 25 years to the
Dana Farber Cancer Institute, culminating in her role as Executive Vice
President and Chief Operating Officer. Prior to that, she was Chief Financial
Officer and held various financial positions at the Tufts - New England
Medical Center Hospitals. Dorothy served as a Lead Director at Abiomed for c.
20 years, until the successful acquisition of the company by JNJ. As a Lead
Director of Abiomed, Dorothy worked closely with the management team and other
Board members to set strategic goals and overall direction. In addition to
Abiomed, Dorothy served on the boards of BCBS, Azenta and Reebok. She was on
the adjunct faculty at Harvard School of Public Health for many years.

Karen Flynn brings more than three decades of commercial and operations
experience to the board of Germfree. Most recently, she served as Interim
President of BioModalities at Catalent. Preceding this role, Karen held
positions as Chief Commercial Officer and President of Biologics at Catalent.
Prior to her tenure at Catalent, she served as Senior Vice President and Chief
Commercial Officer for West Pharmaceutical Services, also assuming the role of
President of its Pharmaceutical Packaging Systems business. Besides her
involvement with Germfree's board, Karen currently holds positions on the
Boards of Quanterix Corporation and Sotera Health.

Kerry Ingalls is a pharma veteran who brings experience across manufacturing
and operations. He previously served as Chief Operating Officer of Poseida
Therapeutics, overseeing corporate strategic planning, operations, and the
construction, commissioning, and licensing of the CGT manufacturing plant.
Prior to his time at Poseida, Kerry held various leadership positions at Amgen
for many years, managing multiple operations sites and overseeing all clinical
and commercial GMP manufacturing at Amgen's global headquarters. Before
joining Amgen, Kerry had a distinguished career in the US Navy.

Helga Salling presently holds the position of Vice President, Global Growth
& Strategy- Life Sciences at Jacobs. With over 20 years of experience in
the Life Sciences sector, Helga brings valuable expertise to the Germfree
Board. Before joining Jacobs, Helga served as VP Integrated Projects at IPS,
and before that, she held positions at DPS Group and served as COO at Advent
Engineering.

"We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of
Directors. They bring decades of experience, leadership and strategic thinking
in key markets that Germfree serves. We are thrilled to be working with them
as we aggressively scale the business to meet the needs of our customers, in
particular in the cell and gene therapy space," said Evis Hursever, Managing
Director at EW Healthcare Partners and Chair of the Board of Directors.

About Germfree

Germfree has become a globally recognized authority in cutting-edge critical
environment equipment, cleanrooms, and laboratories for over six decades. The
company has consistently led the way in pioneering cleanroom design and
manufacturing, serving the biopharmaceutical, healthcare, and research
sectors. Germfree remains resolutely committed to providing innovative
solutions that significantly improve patient access to life-changing
therapies.

About EW Healthcare Partners

With over $2 billion of capital raised since 2014, EW Healthcare Partners
seeks to make growth equity investments in fast-growing commercial-stage
healthcare companies in the pharmaceutical, medical device, diagnostics, and
technology-enabled services sectors in the United States and in Europe. EW
Healthcare Partners has a singular commitment to the healthcare industry and
has been a long-term investor in numerous healthcare companies, ranging across
sectors, stages and geographies. The team of senior investment professionals,
operating partners and advisors is based in New York, London and Houston.
https://www.ewhealthcare.com/
(https://stats.nwe.io/x/html?final=aHR0cHM6Ly93d3cuZXdoZWFsdGhjYXJlLmNvbS8&sig=EdbuEL-eAaYP5Xw00Y82v3M4-I6l2VHy0jtjCFvX_tsBMc5HPJxDetwiYdkbWK3uwudpE87khxAsE0tI5EPUgA&hit%2Csum=WyI0N3c5enYiLCI0N3c5enciLCI0N3c5engiXQ)

Media Contact

Lauren Blum, Content Marketing Manager at Germfree

+1 386-265-4300

Marketing@germfree.com

www.germfree.com

Contact Information

Lauren Blum

Content Marketing Manager

lblum@germfree.com

+1 386-265-4300

SOURCE: Germfree

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMZGZZRNZGDZM